Agreed! 👍🏼👏👏👏

I’d love to see more emphasis on hard, pre-specified endpoints for “tolerability” and “manageable” if we are going to use such terms. Too often it seems arbitrary after the fact. In my IITs we have safety monitoring rules, so we can address obs vs. exp AEs.

Ig__ expressing LP cells in NLPHL are associated with ___
#HemePath #PathTwitter #Pathology

There are many lanes which we, as practicing physicians, can/should be in, but advertising drugs is not one of them …

Congratulations to Christine Auberle, one of our outstanding WashU Heme/Onc Fellowship on the publication of her analysis of the Clinical Trial Development Program for WashU Heme/Onc Fellowship published in Academic Medicine #MedEd
✅118 fellows submitted a trial 'Letter of Intent'
☑️79% obtained

👀, year of the bispecifics?

Great story in Nature on #CancerVaccine #Immunotherapy w contributions from Levy Lab Stanford Medicine, Sandra Demaria Weill Cornell Medicine, Genentech and the teams at Mount Sinai Health System and Lipschultz Precision Immunology Institute ! nature.com/articles/d4158…

Featuring my boss Fehniger Lab!

NK-cell therapies are safer than T-cell therapies and offer other advantages but require upgrades to overcome their limited lifespan and susceptibility to immunosuppression nature Amanda Keener
nature.com/articles/d4158…

Wow, big news!

As I recently wrote about, we don't know if blood-based cancer screening works.
theatlantic.com/health/archive…

New journal club: Lim and Jeon discuss a recent study demonstrating the utility of noninvasive genomic profiling for subtyping #HodgkinLymphoma

Link: bit.ly/3yBkA3K

Seoul National University

Tune in to our new episode on updates in primary myelofibrosis with the MPN legend Dr. Ayalew Tefferi! We discussed navitoclax, pelabresib, & selinexor, along with practical tips on PMF management.

tinyurl.com/2muy3b72

👇Check out this clip on trial endpoints in PMF!

New Research: 4-year follow-up of GAIA/CLL13:

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic #leukaemia thelancet.com/journals/lanon…

#CLL #leusm

A challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs). A study in Nature Biotechnology predicts (TCRs) based on single-cell RNA sequencing and single-cell T cell receptor sequencing. go.nature.com/4bbKkSP

Time w/ Max Diehn, MD/PhD & Ash Alizadeh, MD/PhD 🇺🇸 was foundational. Grateful for Doris Duke Foundation support + stellar co-authors in getting our work out npj Journals Precision Onc rdcu.be/dJfK8

Johns Hopkins Neurosurgery Stanford Cancer Institute Stanford Neurosurgery

🥂honored to receive Conquer Cancer, the ASCO Foundation ASCO Career Development Award to support IIT using ctDNA🧬🩸(collab w/ Foresight Diagnostics Inc.) to de-escalate standard 1L txt for DLBCL! Thx to all my mentors Barbara Pro Alex Herrera Jennifer Amengual Jason Westin, MD FACP Michael Green, PhD Nitin Jain #lymsm #ASCO24

In some cases, in the design of clinical trials, crossover should be not only allowed, it should be mandatory.
Crossover for pts in the control arm has methodological and ethical issues.
Have a look at my commentary.
OncoAlert

acsjournals.onlinelibrary.wiley.com/doi/full/10.10…